Neuroimmunology Drugs Market worth $37.32 billion by 2030 - Exclusive Report by InsightAce Analytic
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: PR Newswire
JERSEY CITY, N.J., July 6, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Neuroimmunology Drugs Market By Indication (Alzheimer's disease (A.D.), Multiple Sclerosis (M.S.), Parkinson's Disease (P.D.), Myasthenia Gravis (M.G.), Neuromyelitis Optica Spectrum Disorder (NMOSD), Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Amyotrophic Lateral Sclerosis (ALS), and Others), Product Type (Small Molecules, Monoclonal Antibodies, Recombinant Protein, and Others))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."According to the latest research by InsightAce Analytic, global neuroimmunology drugs market is valued at US$ 20.78 billion in 2021, and it is expected to reach US$ 37.32 billion by 2030, with a CAGR of 6.93% during the forecast period of 2022-2030.Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1171 Neuroimmunologica
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- The Galien Foundation Announces 2024 Prix Galien International Awards NomineesPR Newswire
- Exscientia plc (NASDAQ: EXAI) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $7.00 price target on the stock.MarketBeat
- The Race Between Biotech And Techbio [Forbes]Forbes
- Investigation into Exscientia Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to KnowGlobeNewswire
- Investors who lost money on Exscientia plc should contact Levi & Korsinsky about an ongoing investigation - EXAIAccesswire
EXAI
Earnings
- 3/21/24 - Beat
EXAI
Sec Filings
- 4/24/24 - Form 144
- 4/22/24 - Form 6-K
- 4/8/24 - Form 144
- EXAI's page on the SEC website